Amidst AbbVie's $63 billion takeover of Allergan, much has been made of likely business drivers like Botox and eye drug Restasis. But another Allergan med—the next-gen antipsychotic Vraylar—is ...
AbbVie's longstanding alliance with Hungarian drugmaker Gedeon Richter has already given it one blockbuster medicine – Vraylar for schizophrenia and bipolar disorder – and the two partners have just ...
AbbVie’s Allergan-acquired antipsychotic medicine Vraylar is already going gangbusters in its two approved indications. An expansion into tough-to-treat depression, meanwhile, would only build on the ...
DUBLIN and BUDAPEST, Hungary, Sept. 17, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. announced today that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ ...
Please provide your email address to receive an email when new articles are posted on . Allergan recently announced that Vraylar, a once-daily oral atypical antipsychotic, is now available by ...
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant ...
A Phase 3 Study 3111-301-001 showed a clinically and statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients ...
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy. The Food and Drug ...
The sNDA included findings from the RGH-MD-53, RGH-MD-54, and RGH-MD-56 trials in which cariprazine was associated with greater improvement in change from baseline to week 6 on the Montgomery Asberg ...
NEW ORLEANS -- Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, ...
Compared with monotherapy, amisulpride plus olanzapine (Zyprexa) for 16 weeks significantly improved Positive and Negative Syndrome Scale total score in patients with schizophrenia -- but they also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results